Edition:
United States

BIOLASE Inc (BIOL.OQ)

BIOL.OQ on NASDAQ Stock Exchange Capital Market

0.46USD
11:13am EST
Change (% chg)

$0.03 (+6.06%)
Prev Close
$0.43
Open
$0.42
Day's High
$0.48
Day's Low
$0.42
Volume
6,468
Avg. Vol
34,464
52-wk High
$1.87
52-wk Low
$0.32

Summary

Name Age Since Current Position

Jonathan Lord

61 2017 Chairman of the Board

Harold Flynn

50 2015 President, Chief Executive Officer

John Beaver

53 2017 Chief Financial Officer, Senior Vice President

Brendan O'Connell

38 2015 Vice President - Finance and Corporate Controller

Holger Arens

54 2016 Vice President, Managing Director of Europe, the Middle East and Africa

James Surek

2017 Vice President - Sales, Americas

Michael Roux

2016 Vice President of Marketing

Matthew Wilson

2016 Vice President of Human Resources

Samuel Low

2016 Vice President - Dental and Clinical Affairs, Chief Dental Officer

George Bickerstaff

61 2014 Director

Tamar Howson

68 2014 Director

Terence Kelly

54 2014 Director

Richard Lanman

62 2017 Director

James Talevich

2013 Independent Director

Biographies

Name Description

Jonathan Lord

Harold Flynn

Mr. Harold C. Flynn, Jr., is President and Chief Executive Officer of Biolase, Inc., effective July 13, 2015. Prior to joining the Company, Mr. Flynn has been President of Zimmer Dental, a leading manufacturer and provider of medical devices for the dental market including dental implants, prosthetics, and a range of other oral rehabilitation products. Previously, from 2004-2007, he was Divisional Vice President and General Manager at Abbott Hematology, a division of Abbott Laboratories. Mr. Flynn holds a Bachelor of Science degree in Electrical Engineering from the University of Maine at Orono. He holds patents in hematology and implantable devices for dentistry. He lives with his family in Encinitas, CA.

John Beaver

Mr. John R. Beaver is Chief Financial Officer, Senior Vice President of the Company. Mr. Beaver, brings proven leadership and technical experience in finance and business management in both public and private companies. Prior to joining BIOLASE, Mr. Beaver served as the Chief Financial Officer of San Jose, CA-based Silicor Materials, Inc., a global leader in the production of solar silicon, from 2009 to 2013 and from 2015 to 2017. He also served on Silicor's Board of Directors from 2013 to 2015. While at Silicor, he led debt and equity fundraising efforts to finance the company's transition from start-up to commercial production. He also supported annual revenue growth from zero to approximately $100 million in less than one year, and he developed and implemented many of the company's business processes. Previously, from 2013-2015, Mr. Beaver was Chief Financial Officer for Seattle-based Modumetal, Inc., a nano-laminated alloy coatings company focused on oil and gas applications. At Modumetal, he led efforts to raise more than $50 million in debt and equity to fund the transition from start-up to commercial production. From 2001 to 2007, Mr. Beaver was at Houston-based Sterling Chemicals, Inc., a mid-sized, publicly-traded commodity chemical manufacturer, where he served as Senior Vice President Finance and Chief Financial Officer and prior to that position he was its Vice President, Corporate Controller. He has also held senior financial management positions at Pioneer Companies, Inc., and Borden Chemicals and Plastics. He has a Bachelor of Business Administration degree in Accounting from the University of Texas at Austin and is a Certified Public Accountant.

Brendan O'Connell

Mr. Brendan O'Connell is appointed as Vice President - Finance and Corporate Controller in January 2015. Mr. O’Connell began his career with Biolase as our Assistant Controller in May 2007 and was promoted to serve as our Corporate Controller effective February 2009. Mr. O’Connell earned a Bachelor of Science in Accounting and an M.B.A. from University of California, Riverside.

Holger Arens

Mr. Holger Arens has been appointed as Vice President, Managing Director of Europe, the Middle East and Africa (EMEA) of the Company. Arens, has more than 15 years of experience in a variety of commercial and operational activities in international dental sales and business development. Since 2013, Arens has been consulting with dental and medical technology entrepreneurs, investors and manufacturers in establishing business plans and implementing robust commercial processes to improve the performance of sales and marketing teams. While at KaVo Dental, Arens spearheaded the company's growth in market share, the increase in its after-sales service business in Europe, and the expansion of its footprint in emerging markets in EMEA, especially in Eastern Europe and the Middle East. Arens also oversaw the design and implementation of a European training center, the reshaping of the European organization's programs to increase competitiveness, and he regularly participated in M&A activities. Prior to KaVo, Arens spent 10 years in roles of increasing responsibility with 3M Deutschland where he was introduced to the dental business when 3M acquired Unitek. Arens has a degree in Business Administration from the University of Applied Science in Dusseldorf, Germany. From 1999 to 2013, Arens was with KaVo Dental GmbH, based in Biberach, Germany, where he held executive positions of increasing responsibility, being promoted to Vice President of Sales and Service EMEA in 2010. During his tenure in that position, he led a turnaround and significantly grew sales and profitability up to and after its acquisition by Danaher Corporation.

James Surek

Michael Roux

Mr. Michael Roux is Vice President of Marketing of the company. He has significant leadership experience in marketing and product management and comes to BIOLASE with a wide range of medical device and multinational business expertise with leading publicly-owned companies. Most recently, Mr. Roux served for three years as Vice President of Product Management with Patient Safety Technologies, which was acquired by Stryker in 2014. Prior to that, Mr. Roux spent four years as Global Product Director for the Respiratory Care franchise of Hill-Rom, and 19 years at 3M Company where he held positions of increasing responsibility within product engineering, six-sigma, global product marketing leadership and business development groups. Mr. Roux holds a Bachelor of Science Degree in Industrial Engineering from the University of Minnesota, and a Masters of Business Administration in Marketing from the University of St. Thomas.

Matthew Wilson

Mr. Matthew Wilson is Vice President of Human Resources of the company. He brings over 15 years of experience in Human Resources Management in diverse industries, including dental medical device, commercial real estate and aerospace. Most recently, Mr. Wilson served for nearly eight years as Human Resources Director for the Zimmer Biomet, Inc. (previously Zimmer, Inc.) dental business. Prior to that role, Mr. Wilson spent over three years at CBRE Group, Inc. as Human Resources Director and Senior Organization Development Consultant. Mr. Wilson began his career in Human Resources in Raytheon Company's two-year Human Resources Leadership Development Program, followed by an additional three years as Principal Human Resources Generalist for the company's Integrated Airborne Systems organization. Mr. Wilson holds a Masters of Business Administration in International Management from Thunderbird School of Global Management and a Bachelor of Arts in Marketing from the University of Utah.

Samuel Low

Dr. Samuel B. Low, D.D.S., M.S., M.Ed., serves as Vice President - Dental and Clinical Affairs, Chief Dental Officer of the Company. He was Independent Director of the company. Dr. Low is Professor Emeritus, University of Florida, College of Dentistry and Associate faculty member of the Pankey Institute, with 30 years of private practice experience in periodontics, lasers and implant placement. He is also a Diplomate of the American Board of Periodontology and past President of the American Academy of Periodontology. Dr. Low provides dentists and dental hygienists the tools for successfully managing the periodontal patient in general and periodontal practices. He was selected "Dentist of the Year" by the Florida Dental Association, Distinguished Alumnus by the University of Texas Dental School, and the Gordon Christensen Lecturer Recognition Award. He is a Past President of the Florida Dental Association and past ADA Trustee. Dr. Low received his Doctor of Dental Surgery (D.D.S.) and Master of Science (M.S.) degrees from the University of Texas at Houston. He also completed his residency in Periodontics at the University of Texas at Houston, and received a Masters of Education from the University of Florida.

George Bickerstaff

Mr. George W. Bickerstaff, III, is appointed as Director of Biolase Inc., effective June 16, 2014. Mr. Bickerstaff is currently a Managing Director of M.M. Dillon & Co., LLC, which he joined in 2005. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global pharmaceuticals and consumer health company, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005. From December 1999 to September 2000, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Workscape, Inc. a provider of employee-related information services. From July 1998 to December 1999, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Uniscribe Professional Services, Inc., a nationwide provider of paper and technology-based document management solutions. From January 1998 to June 1998, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Intellisource Group, Inc., a provider of information technology solutions to the federal, state and local government and utility markets. From July 1997 to December 1997, Mr. Bickerstaff served as Vice President of Finance of Cognizant Corporation, a global business information services company. From January 1990 to June 1997, Mr. Bickerstaff served in various senior finance roles, including Chief Financial Officer of IMS Healthcare, a global business information services company in the healthcare and pharmaceutical industries. Prior to that, Mr. Bickerstaff held various finance, audit and engineering positions with the Dun & Bradstreet Corporation and General Electric Company. Mr. Bickerstaff has been a member of the board of directors of CareDx, Inc., a company that develops, markets, and delivers diagnostic surveillance solutions for organ transplant recipients, since April 2014. Mr. Bickerstaff holds a B.S. in Engineering and a B.A. in Business Administration from Rutgers University (1978).

Tamar Howson

Ms. Tamar D. Howson is appointed as Director of Biolase Inc., effective June 16, 2014. She has served as an independent corporate business development and strategy consultant to life science companies since 2011. From 2009 to 2011, she provided business development support to life sciences companies as a member of the transaction team at JSB-Partners. From 2007 to 2008, Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals. From 2001 to 2007, Ms. Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb. From 1991 to 2000, Ms. Howson served in various business development executive positions at SmithKline Beecham, including Senior Vice President and Director, Business Development. Ms. Howson also managed SmithKline Beecham’s venture capital fund, SR-One. Prior to that, Ms. Howson served in various business development, investment, and engineering positions at Johnston Associates, Squibb Corporation, FMC Corporation, and Envirotech Corporation. Ms. Howson currently serves on the board of directors of the following publicly traded companies: Actavis plc, Idenix Pharmaceuticals Inc., OXiGENE, Inc., and Organovo Holdings, Inc. Additionally, she is a director of the International Partnership for Microbicides, a non-profit product development organization. Ms. Howson was previously a member of board of directors of the following publicly traded corporations: Warner Chilcott plc from May 2013 until she joined the board of directors of Actavis plc in October 2013; Aradigm Corporation from November 2010 to April 2013; Soligenix, Inc. from September 2010 to January 2013; and BioLineRx Ltd. from August 2007 to June 2009. Ms. Howson holds an MBA from Columbia University (1980), an M.S. in Chemical Engineering from the City College of New York (1976), and a B.S. in Chemical Engineering from Technion - Israel Institute of Technology (1973).

Terence Kelly

Dr. Terence A. Kelly, Ph.D., is appointed as Director of Biolase Inc., effective June 16, 2014. He has over 20 years of experience as a scientist and executive in the pharmaceutical industry starting as a medicinal chemist in 1990. Dr. Kelly is currently the President and Chief Executive Officer of CoMentis, Inc., a venture-backed private biotech company focused on neurodegenerative diseases, and a founder of Kelly Pharma Research Consulting, LLC. From 1990 to 2009, Dr. Kelly served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department, which included 145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups. Dr. Kelly holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute (1982) and a Ph.D. degree in Chemistry at the University of Texas at Austin (1988). He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University, Stern School of Business (1998). Dr. Kelly is the co-author of over 25 scientific publications and serves on the College of Natural Sciences Advisory Council for the University of Texas.

Richard Lanman

Dr. Richard (Rick) B. Lanman M.D., is Director of the Company. From July 2008 until September 2014 Dr. Lanman was with Veracyte, Inc., where he drove the validation and clinical utility studies required to commercialize genomic diagnostics in thyroid and lung neoplasia that facilitate improved diagnosis utilizing small, minimally-invasive biopsies. Veracyte went public in 2013. He also previously served as Chief Medical Officer for two cardiovascular biodiagnostic companies, diaDexus and Atherotech, and prior to that, Dr. Lanman was the medical director and senior vice president of San Jose Medical Group and a Chief of Quality at Kaiser Permanente. Dr. Lanman completed his internship and residency at the University of California San Francisco, after receiving his medical degree from Northwestern University and a Bachelor of Science in chemistry from Stanford University, where he graduated Phi Beta Kappa.

James Talevich

Mr. James R. Talevich is Independent Director of the Company. Mr. Talevich currently serves on the board of directors of Nova LifeStyle, Inc. (STVS.PK), an international manufacturing company. Mr. Talevich currently serves as a member of the Executive Committee and Advisory Council of the SEC Financial Reporting Institute at the USC Marshall School of Business, and as a member of the UCLA Anderson School of Management Alumni Board of Directors. Prior to his current roles, he served as Chief Financial Officer of I-Flow Corporation, a NASDAQ-listed medical technology company, from 2000 to 2009, Chief Financial Officer of Tectrix Fitness Equipment Inc. from 2005 to 2009, and Chief Financial Officer of Gish Biomedical, Inc., a NASDAQ-listed manufacturing company, from 1999 to 2000. From 2008 to 2009, he served on the Board of Directors of AcryMed, Inc., a developer of antimicrobial nanoparticle technologies. Mr. Talevich received a B.A. in physics from California State University, Fullerton, and an MBA from the UCLA Anderson School of Management. He is licensed as a Certified Public Accountant. There are no understandings or arrangements between Mr. Talevich or any other person and the Company or any of its subsidiaries pursuant to which Mr. Talevich was selected to serve as a director of the Company. There are no family relationships between Mr. Talevich and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer, and there are no transactions between Mr. Talevich or any of his immediate family members and the Company or any of its subsidiaries.